What Killexams.com Experts says about BCBA test prep | | Inicio RADIONAVES

Killexams.com BCBA PDF and exam test system are MUST HAVE for test prep It contains braindumps and practice test for new course substance - Killexams.com - - Inicio RADIONAVES

Pass4sure BCBA dumps | Killexams.com BCBA real questions | http://www.radionaves.com/

BCBA Board Certification in commerce Valuation(R) (BCBA)

Study steer Prepared by Killexams.com Real-Estate Dumps Experts


Killexams.com BCBA Dumps and real Questions

100% real Questions - Exam Pass Guarantee with towering Marks - Just Memorize the Answers



BCBA exam Dumps Source : Board Certification in commerce Valuation(R) (BCBA)

Test Code : BCBA
Test name : Board Certification in commerce Valuation(R) (BCBA)
Vendor name : Real-Estate
: 251 real Questions

Right dwelling to find BCBA Latest dumps paper.
I exceeded the BCBA exam thanks to this bundle. The questions are accurate, and so are the subjects and purchase a glance at courses. The format could be very convenient and permits you to examine in one-of-a-kind codecs - practising at the trying out engine, studying PDFs and printouts, so that you can exercise session the fashion and stability thats birthright for you. I personally loved practising on the trying out engine. It completely simulates the exam, thats especially vital for BCBA exam, with each and every their specific query sorts. So, its a bendy but reliable way to attain your BCBA certification. Ill be using killexams.com for my subsequent stage certification checks, too.


BCBA exam isn't any greater tough with these QAs.
The solutions are explained in short in simple language and nonetheless develop pretty an impact thats immaculate to understand and observe. I took the befriend of killexams.com and exceeded my BCBA exam with a wholesome rating of sixty nine. way to killexams.com . I would really enjoy to bespeak in favor of killexams.com for the practise of BCBA examination


it's miles unbelieveable, but BCBA today's dumps are availabe birthright here.
Phrase of mouth is a very strong manner of advertising and advertising for a product. I say, whilst some thing is so suitable, why no longer enact a petite towering fine publicity for it I would really enjoy to unfold the word approximately this one in every of a kindhearted and definitely extremely trustworthy killexams.Com which helped me in appearing outstandingly well in my BCBA examination and exceeding each and every expectations. I might squawk that this killexams.Com is one of the maximum admirable on line education ventures i own ever near across and it merits a whole lot of recognition.


What is needed to examine for BCBA examination?
that is my first time that I took this provider. I feel very confident in BCBA but. I build together my BCBA the expend of questions and answers with exam simulator softare via killexams.com team.


Dumps of BCBA exam are available now.
applicants spend months looking to collect themselves prepared for their BCBA assessments however for me it changed into each and every just a days work. youll wonder how someone would own the aptitude to finish this kindhearted of super task in only a day let me inform you, each and every I had to enact turned into sign in myself on this killexams.com and the whole thing changed into precise after that. My BCBA check seemed enjoy a very simple challenge due to the fact i was so nicely prepared for it. I thank this web site for lending me a assisting hand.


discovered an correct source for real BCBA contemporaneous dumps.
I certainly asked it, honed for a week, then went in and surpassed the exam with 89% marks. that is the issue that the proper examination arrangement ought to be much enjoy for each person! I got to be BCBA affirmed accomplice attributable to this web page. theyve an excellent accumulation of killexams.com and examination association property and this time their stuff is exactly as super. The inquiries are valid, and the examination simulator works best. No troubles identified. I suggested killexams.com Steadfast!!


What are requirements to pass BCBA examination in petite attempt?
Killexams.Com substances cowl each factor of BCBA , round which the BCBA exam is built. So if youre novel to it, this is a need to. I needed to step up my expertise of BCBA qa has helped me loads. I exceeded the BCBA examination way to killexams.Com and had been recommending it to my friends and co-workers.


It changed into first revel in however remarkable experience!
I didnt aim to apply any wit dumps for my IT certification assessments, but being underneath strain of the problem of BCBA exam, I ordered this bundle. I was stimulated through the nice of those substances, theyre in fact worth the coins, and that i believe that theyll value greater, this is how notable they are! I didnt own any hassle even astaking my exam thanks to Killexams. I really knew each and every questions and answers! I got ninety seven% with just a few weeks examination education, except having some paintings enjoy, which modified into virtually beneficial, too. So sure, killexams.com is definitely properly and enormously endorsed.


in which am i able to find BCBA dumps questions?
I were given this percent and exceeded the BCBA exam with ninety seven% marks after 10 days. Im quite fulfilled via the conclude result. There may be extremely trustworthy stuff for associate stage confirmations, however regarding the expert level, I matter on that is the precept strong aim of action for high-quality stuff, particularly with the exam simulator that gives you a danger to drill with the advent and sustain of a real examination. That is a definitely substantial brain dump, genuine keep manual. That is elusive for cutting aspect exams.


where am i able to find keep steer for exact knowledge of BCBA exam?
Id advise this query bank as a should must each and every and sundry who is preparing for the BCBA exam. It became very profitable in getting an concept as to what configuration of questions were coming and which regions to interest. The drill check provided was besides brilliant in getting a sustain of what to await on examination day. As for the solutions keys supplied, it become of first rate befriend in recollecting what I had learnt and the explanations provided own been simple to understand and definately brought freight to my concept on the difficulty.


Real-Estate Real-Estate Board Certification in

true property utility market set to develop based on forecasts | killexams.com real Questions and Pass4sure dumps

This document reviews precise estate utility in world market, exceptionally in North the us, Europe, China, Japan, Korea and Taiwan, specializes in precise producers in world market, with skill, production, price, income and market share for each company, masking Intel

The record on precise estate utility market is an all-inclusive glance at of the latest scenario of the commerce with the bottom 12 months being 2019 and its growth possibilities over 2019-2025. The file is a painstaking recreation to present a comprehensive overview of real property application market in accordance with boom alternatives and market shares.

This record offers an in-depth research about the standard state of suitable property utility market and tasks an silhouette of its growth market. It besides gives the faultfinding points of the market and throughout most Important world regions in detail.

number on fundamental and secondary analysis has been conducted with the aim to compile required statistics for completing this particular document. Sever industry based mostly analytical suggestions has been narrowed down for a stronger realizing of this market.

file: www.researchnreports.com/request_sample.personal home page?id=77337

companies Profiled in this record includes    Intel

    Qualcomm

    NXP Semiconductors

    Texas contraptions

    Cypress Semiconductor

    Mediatek

    Microchip technology

    Renesas Electronics

    Stmicroelectronics

    Huawei applied sciences

    Nvidia

    advanced Micro devices

    Samsung Electronics

The evolution of more suitable products and multiplied affected person effects has resulted due to the competitive environment in the market.

The document covers real estate utility market from the bottom line, starting from its definition. Later, it segments the market on a lot of standards to supply a depth of knowing on the a number of product types and pricing structures and purposes.

each and every angle is examined cautiously by factoring in income, earnings and market dimension so as to own in wit the talents of boom and scope.

file: www.researchnreports.com/.Hypertext Preprocessor?id=77337

 

motive to access precise property software Market research file:

analysis of actual estate application market and its upcoming boom possibilities is been outlined with maximum precision. This glance at contains an elaborative abstract of market which additionally contains snapshots that present depth of information of a lot of other segmentations.

through qualitative and quantitative evaluation of key components which are liable for boosting or hampering the market growth and the promising alternatives in market were give. primary and secondary research is been done in aspect which helps the readers own a powerful realizing of the comprehensive market for the forecast duration.

desk of Contents

world actual property application Market analysis file

Chapter 1 suitable property application Market Overview   

Chapter 2 international financial own an impact on on trade   

Chapter 3 international Market competitors by using manufacturers 

Chapter four international construction, salary (price) via location

Chapter 5 international deliver (construction), Consumption, Export, Import by using regions 

Chapter 6 world construction, profits (value), fee fashion by using class   

Chapter 7 world Market evaluation with the aid of application   

Chapter 8 Manufacturing can freight evaluation   

Chapter 9 Industrial Chain, Sourcing approach and Downstream patrons   

Chapter 10 marketing approach evaluation, Distributors/traders 

Chapter 11 Market result factors analysis   

Chapter 12 global actual property application Market Forecast

record: www.researchnreports.com/.personal home page?identification=77337

This electronic mail address is being blanketed from spambots. You want JavaScript enabled to view it.


Morguard actual estate funding own faith broadcasts CFO Transition | killexams.com real Questions and Pass4sure dumps

No outcomes discovered, try novel keyword!MISSISSAUGA, ON, Nov. 12, 2018 /CNW/ - The Board of Trustees of the Morguard suitable estate funding believe (the "have confidence") (TSX: MRT.UN) these days announced that it has authorized a main monetary Officer ("C...

precise property : If I change my intellect about renting a spot, can they maintain my deposit? | killexams.com real Questions and Pass4sure dumps

Q: They were going to rent a home in a condo community. They stuffed out the application and left a $250 deposit. a number of days later, they were counseled that they had been accepted and vital to pay an extra $850 for the deposit. They went and left the assess but could not finalize the rent because the supervisor become no longer on the office. Over the weekend, they determined that they didn't are looking to appoint there and referred to as Monday to exact for their money back. they are refusing. Can they maintain their funds? — Linda

A: No, doubtless not, or at least now not most of it. i am going to expend this opening to restate some tips that I can not show to squawk satisfactory: enact not signal anything unless and until you examine it and purchase note what it says.

in case you aren't sure what it ability, enact not signal except you do. i am going to high-tail out on a limb and matter on that your initial $250 “deposit” turned into an “software price,” which you agreed to pay somewhere within the pleasant print of the multi-web page utility. If here is correct, you own got already spent those $250, and they are gone. you should review your reproduction of the kindhearted (at each and every times collect a copy of every thing you signal!) and validate this. If it became a deposit and not a charge, be sure you be in a position to collect it returned.

The $850 assess goes to depend upon if and what you signed in case you dropped off the assess. in case you simply left it with the workplace and did not sign the lease documents, they'll need to revert your cash. despite the fact, if you signed a lease, you may be accountable in your deposit and even some hire, depending on the phrases of the shrink you signed.

You may additionally own besides signed, both on the time of utility or for those who dropped off the 2nd assess, a “reservation” kindhearted that holds the unit for you until a lease is utterly signed. If here is the case, you'll should evaluation the terms of the reservation to peer when you are entitled to money back.

———

concerning the author

Gary M. Singer is a Florida attorney and board-licensed as an authority in actual property legislation by the Florida Bar. He practices actual property, company litigation and shrink legislations from his office in wreck of day, Fla. he is the chairman of the real property component to the Broward County Bar association and is a co-host of the weekly radio array prison intelligence and evaluation. He commonly consults on established suitable estate concerns and developments in Florida with various groups throughout the nation. route him questions on-line at www.sunsentinel.com/askpro or result him on Twitter @GarySingerLaw.

Copyright 2018 Tribune content material agency.


BCBA Board Certification in commerce Valuation(R) (BCBA)

Study steer Prepared by Killexams.com Real-Estate Dumps Experts


Killexams.com BCBA Dumps and real Questions

100% real Questions - Exam Pass Guarantee with towering Marks - Just Memorize the Answers



BCBA exam Dumps Source : Board Certification in commerce Valuation(R) (BCBA)

Test Code : BCBA
Test name : Board Certification in commerce Valuation(R) (BCBA)
Vendor name : Real-Estate
: 251 real Questions

Right dwelling to find BCBA Latest dumps paper.
I exceeded the BCBA exam thanks to this bundle. The questions are accurate, and so are the subjects and purchase a glance at courses. The format could be very convenient and permits you to examine in one-of-a-kind codecs - practising at the trying out engine, studying PDFs and printouts, so that you can exercise session the fashion and stability thats birthright for you. I personally loved practising on the trying out engine. It completely simulates the exam, thats especially vital for BCBA exam, with each and every their specific query sorts. So, its a bendy but reliable way to attain your BCBA certification. Ill be using killexams.com for my subsequent stage certification checks, too.


BCBA exam isn't any greater tough with these QAs.
The solutions are explained in short in simple language and nonetheless develop pretty an impact thats immaculate to understand and observe. I took the befriend of killexams.com and exceeded my BCBA exam with a wholesome rating of sixty nine. way to killexams.com . I would really enjoy to bespeak in favor of killexams.com for the practise of BCBA examination


it's miles unbelieveable, but BCBA today's dumps are availabe birthright here.
Phrase of mouth is a very strong manner of advertising and advertising for a product. I say, whilst some thing is so suitable, why no longer enact a petite towering fine publicity for it I would really enjoy to unfold the word approximately this one in every of a kindhearted and definitely extremely trustworthy killexams.Com which helped me in appearing outstandingly well in my BCBA examination and exceeding each and every expectations. I might squawk that this killexams.Com is one of the maximum admirable on line education ventures i own ever near across and it merits a whole lot of recognition.


What is needed to examine for BCBA examination?
that is my first time that I took this provider. I feel very confident in BCBA but. I build together my BCBA the expend of questions and answers with exam simulator softare via killexams.com team.


Dumps of BCBA exam are available now.
applicants spend months looking to collect themselves prepared for their BCBA assessments however for me it changed into each and every just a days work. youll wonder how someone would own the aptitude to finish this kindhearted of super task in only a day let me inform you, each and every I had to enact turned into sign in myself on this killexams.com and the whole thing changed into precise after that. My BCBA check seemed enjoy a very simple challenge due to the fact i was so nicely prepared for it. I thank this web site for lending me a assisting hand.


discovered an correct source for real BCBA contemporaneous dumps.
I certainly asked it, honed for a week, then went in and surpassed the exam with 89% marks. that is the issue that the proper examination arrangement ought to be much enjoy for each person! I got to be BCBA affirmed accomplice attributable to this web page. theyve an excellent accumulation of killexams.com and examination association property and this time their stuff is exactly as super. The inquiries are valid, and the examination simulator works best. No troubles identified. I suggested killexams.com Steadfast!!


What are requirements to pass BCBA examination in petite attempt?
Killexams.Com substances cowl each factor of BCBA , round which the BCBA exam is built. So if youre novel to it, this is a need to. I needed to step up my expertise of BCBA qa has helped me loads. I exceeded the BCBA examination way to killexams.Com and had been recommending it to my friends and co-workers.


It changed into first revel in however remarkable experience!
I didnt aim to apply any wit dumps for my IT certification assessments, but being underneath strain of the problem of BCBA exam, I ordered this bundle. I was stimulated through the nice of those substances, theyre in fact worth the coins, and that i believe that theyll value greater, this is how notable they are! I didnt own any hassle even astaking my exam thanks to Killexams. I really knew each and every questions and answers! I got ninety seven% with just a few weeks examination education, except having some paintings enjoy, which modified into virtually beneficial, too. So sure, killexams.com is definitely properly and enormously endorsed.


in which am i able to find BCBA dumps questions?
I were given this percent and exceeded the BCBA exam with ninety seven% marks after 10 days. Im quite fulfilled via the conclude result. There may be extremely trustworthy stuff for associate stage confirmations, however regarding the expert level, I matter on that is the precept strong aim of action for high-quality stuff, particularly with the exam simulator that gives you a danger to drill with the advent and sustain of a real examination. That is a definitely substantial brain dump, genuine keep manual. That is elusive for cutting aspect exams.


where am i able to find keep steer for exact knowledge of BCBA exam?
Id advise this query bank as a should must each and every and sundry who is preparing for the BCBA exam. It became very profitable in getting an concept as to what configuration of questions were coming and which regions to interest. The drill check provided was besides brilliant in getting a sustain of what to await on examination day. As for the solutions keys supplied, it become of first rate befriend in recollecting what I had learnt and the explanations provided own been simple to understand and definately brought freight to my concept on the difficulty.


Unquestionably it is difficult assignment to pick dependable certification questions/answers assets regarding review, reputation and validity since individuals collect sham because of picking incorrectly benefit. Killexams.com ensure to serve its customers best to its assets concerning exam dumps update and validity. The vast majority of other's sham report dissension customers near to us for the brain dumps and pass their exams joyfully and effortlessly. They never trade off on their review, reputation and attribute on the grounds that killexams review, killexams reputation and killexams customer assurance is imperative to us. Uniquely they deal with killexams.com review, killexams.com reputation, killexams.com sham report objection, killexams.com trust, killexams.com validity, killexams.com report and killexams.com scam. On the off haphazard that you survey any indecent report posted by their rivals with the name killexams sham report grievance web, killexams.com sham report, killexams.com scam, killexams.com protest or something enjoy this, simply remember there are constantly terrible individuals harming reputation of trustworthy administrations because of their advantages. There are a huge number of fulfilled clients that pass their exams utilizing killexams.com brain dumps, killexams PDF questions, killexams hone questions, killexams exam simulator. Visit Killexams.com, their specimen questions and test brain dumps, their exam simulator and you will realize that killexams.com is the best brain dumps site.


Vk Profile
Vk Details
Tumbler
linkedin
Killexams Reddit
digg
Slashdot
Facebook
Twitter
dzone
Instagram
Google Album
Google About me
Youtube



310-100 real questions | 3101 braindumps | 000-080 exam prep | 000-997 drill Test | 1Z0-506 sample test | 000-176 questions and answers | 1Y0-401 study guide | HP0-J48 real questions | C9530-001 drill exam | BCP-221 free pdf | HP2-E41 dump | 000-561 exam prep | 000-N04 real questions | C2180-607 mock exam | C2020-642 free pdf | HP0-500 brain dumps | EPPP drill questions | 650-621 brain dumps | 000-537 cram | M9510-747 drill test |


BCBA | BCBA | BCBA | BCBA | BCBA | BCBA

Real BCBA questions that appeared in test today
We own Tested and Approved BCBA Exams. killexams.com gives the most specific and most recent IT exam materials which nearly comprise each and every exam topics. With the database of their BCBA exam materials, you enact not own to squander your opening on perusing time consuming reference books and surely need to char thru 10-20 hours to ace their BCBA real questions and answers.

Are you searching for Real-Estate BCBA Dumps containing real exam Questions and Answers for the Board Certification in commerce Valuation(R) (BCBA) test prep? they present most updated and attribute supply of BCBA Dumps that's http://killexams.com/pass4sure/exam-detail/BCBA. they own got compiled an information of BCBA Dumps questions from actual tests so as to allow you to prepare and pass BCBA exam on the first attempt. killexams.com Discount Coupons and Promo Codes are as under; WC2017 : 60% Discount Coupon for each and every exams on website PROF17 : 10% Discount Coupon for Orders larger than $69 DEAL17 : 15% Discount Coupon for Orders larger than $99 SEPSPECIAL : 10% Special Discount Coupon for each and every Orders You ought to collect the recently updated Real-Estate BCBA Braindumps with the correct answers, that are ready via killexams.com specialists, helping the candidates to understand and sustain regarding their BCBA exam path, you will not realize BCBA exam of such attribute within the marketplace. Their Real-Estate BCBA brain Dumps are given to candidates at acting 100% of their test. Their Real-Estate BCBA exam dumps are working distinguished within the test centers, providing you with an opening to dwelling along in your BCBA exam.

At killexams.com, they give explored Real-Estate BCBA tutoring assets which can be the best to pass BCBA test, and to collect authorized by Real-Estate. It is an incredible inclination to quicken your vocation as an expert in the Information Technology endeavor. They are content with their notoriety of supporting individuals pass the BCBA exam of their first endeavors. Their prosperity costs in the previous years had been really astonishing, on account of their tickled customers presently ready to support their profession inside the rapid path. killexams.com is the essential decision among IT experts, particularly the individuals trying to high-tail up the progressive system goes quicker in their separate companies. Real-Estate is the undertaking pioneer in records age, and getting ensured by them is an ensured approach to win with IT vocations. They enable you to enact precisely that with their unnecessary wonderful Real-Estate BCBA tutoring materials.

Real-Estate BCBA is inescapable each and every around the globe, and the commerce undertaking and programming arrangements given by utilizing them are grasped by mode for about the greater share of the associations. They own helped in driving heaps of organizations on the beyond any doubt shot course of pass. Extensive data of Real-Estate items are taken into preparation a totally urgent capability, and the specialists certified by mode for them are very esteemed in each and every associations.

We present genuine BCBA pdf exam inquiries and answers braindumps in positions. Download PDF and drill Tests. Pass Real-Estate BCBA digital engage Exam rapidly and effortlessly. The BCBA braindumps PDF compose is to be had for perusing and printing. You can print more noteworthy and exercise typically. Their pass rate is towering to 98.9% and the affinity percent between their BCBA syllabus study manual and genuine exam is 90% construct absolutely Considering their seven-yr instructing knowledge. enact you need accomplishments inside the BCBA exam in only one attempt? I am now dissecting for the Real-Estate BCBA genuine exam.

As the only thing in any way Important here is passing the BCBA - Board Certification in commerce Valuation(R) (BCBA) exam. As each and every which you require is a towering score of Real-Estate BCBA exam. The best one angle you own to enact is downloading braindumps of BCBA exam courses now. They will never again will give you a haphazard to down with their cash back guarantee. The specialists moreover protect beat with the greatest forward exam so you can give the vast majority of updated materials. Three months free collect passage to as an approach to them through the date of purchase. Each hopeful may likewise manage the cost of the BCBA exam dumps through killexams.com at a low cost. Regularly there might be a diminish for each and every individuals all.

Within the sight of the suitable exam substance of the brain dumps at killexams.com you may effortlessly grow your specialty. For the IT experts, it's far faultfinding to adjust their abilities reliable with their calling necessity. They develop it smooth for their clients to purchase accreditation exam with the assistance of killexams.com demonstrated and honest to goodness exam material. For a splendid future in its realm, their wit dumps are the distinguished decision.

killexams.com Huge Discount Coupons and Promo Codes are as under;
WC2017: 60% Discount Coupon for each and every exams on website
PROF17: 10% Discount Coupon for Orders greater than $69
DEAL17: 15% Discount Coupon for Orders greater than $99
OCTSPECIAL: 10% Special Discount Coupon for each and every Orders


A best dumps composing is an absolutely imperative component that makes it simple a decent mode to purchase Real-Estate certifications. be that as it may, BCBA braindumps PDF gives accommodation for hopefuls. The IT certification is a significant troublesome task on the off haphazard that one does now not find birthright direction inside the type of certifiable helpful asset material. Along these lines, we've genuine and state-of-the-art content material for the instruction of accreditation exam.

BCBA | BCBA | BCBA | BCBA | BCBA | BCBA


Killexams CHA cram | Killexams 1Y0-327 braindumps | Killexams 920-352 questions and answers | Killexams C2180-319 drill test | Killexams 000-234 study guide | Killexams JN0-102 real questions | Killexams ISEB-BA1 braindumps | Killexams SCNS-EN cheat sheets | Killexams 6007 free pdf | Killexams 000-M86 test prep | Killexams A2180-607 test prep | Killexams 2U00210A examcollection | Killexams HP2-Z22 drill test | Killexams 920-249 dumps | Killexams 1Z0-242 brain dumps | Killexams 000-545 dumps questions | Killexams 250-311 drill questions | Killexams 1D0-441 exam questions | Killexams COG-185 mock exam | Killexams 642-278 free pdf download |


Exam Simulator : Pass4sure BCBA Exam Simulator

View Complete list of Killexams.com Brain dumps


Killexams 1K0-001 study guide | Killexams 3C00120A brain dumps | Killexams HP2-H21 exam questions | Killexams TB0-107 drill questions | Killexams E20-330 real questions | Killexams UM0-300 free pdf | Killexams NS0-310 brain dumps | Killexams 650-042 drill questions | Killexams MB2-184 drill Test | Killexams NSE6 drill test | Killexams 210-065 drill test | Killexams LX0-103 drill exam | Killexams C2010-653 cram | Killexams 1Z0-971 pdf download | Killexams 9L0-066 examcollection | Killexams C9520-423 dumps questions | Killexams MB7-255 questions and answers | Killexams HP0-M46 test questions | Killexams C2140-842 questions answers | Killexams Property-and-Casualty braindumps |


Board Certification in commerce Valuation(R) (BCBA)

Pass 4 sure BCBA dumps | Killexams.com BCBA real questions | http://www.radionaves.com/

Business bulletins: Lubbockites rate promotions and awards | killexams.com real questions and Pass4sure dumps

PSC promotes several in Lubbock

Parkhill, Smith & Cooper has recently promoted several design professionals from its Lubbock office.

Brandon Hartley, AIA, has been promoted to associate. He is a member of the healthcare sector and a BIM coordinator. He has been heavily involved with developing standards to befriend achieve a towering flat of equipment integration and befriend with facilities management through BIM software. Hartley has been with PSC for 10 years.

Michael Krusing, PE, has been promoted to associate. As a team leader in the aviation sector, he pulls from his design and construction oversight expertise to give their clients the selfsame flat of service that helped win the 2015 and 2017 TxDOT Aviation’s Most Improved universal Aviation Airport of the Year. Krusing has designed multiple projects for TxDOT Aviation and novel Mexico Department of Transportation. Krusing has been with PSC for nearly 11 years.

Todd Stiggins, PE, has been promoted to associate. He is a project manager for municipal solid waste in PSC’s environmental sector. His sustain includes engineering design and construction services for over 150 acres of MSW landfill liner, final cover and capital improvement projects in Texas and Oklahoma, including managing project scopes, schedules and budgets in excess of $50 million. Todd has been with PSC for two years and has 15 years of experience. 

^

Galley joins local law firm

Jonathan Galley has joined the law difficult of Craig, Terrill, Hale & Grantham.

The law difficult specializes in civil legal matters.

Galley earned his juris doctorate from the University of Tulsa College of Law and has been licensed for seven years.

Bass named to super attorney list

R. Byrn “Byrnie” Bass, Jr. was selected for the 2018 Texas Super attorney List.

Bass was recognized for his work in commerce bankruptcies. This is the thirteenth time he has been named to the list.

Bass is past chairman of the bankruptcy law section of the State Bar of Texas, past president of the West Texas Bankruptcy Bar Association and besides past president of the Lubbock County Bar Association. In 2013 he was the recipient of the State Bar Bankruptcy Law Section’s Pro Bono Service Award. He graduated from Baylor University in 1969 and received his Law Degree from the University of Texas School of Law in 1972.

Bass besides chaired the 2014 Lubbock zone United Way push and currently serves on the board of directors of the Lubbock Chamber of Commerce.

^

Mears earns national recognition

Nick Mears has been nominated by the National Association of Certified Valuators and Analysts (NACVA) to the 2018 40 Under Forty program.

This program recognizes 40 individuals across the U.S. who are under 40 years outmoded and exemplify the brightest emerging leaders in the commerce valuation profession.

Mears is a managing member and founder of Lubbock-based Caprock commerce Consulting.

"I am honored to be share of this prestigious program and thank you NACVA for your consideration as one of the top emerging leaders in the commerce valuation community across the country," he said.

Submit commerce intelligence to sself-walbrick@lubbockonline.com. Announcements are due Thursday at noon for Sunday publication.


Ionis Pharmaceuticals, Inc. (IONS) Q3 2018 Earnings Conference convoke Transcript | killexams.com real questions and Pass4sure dumps

Logo of jester cap with thought bubble.© The Motley Fool Logo of jester cap with thought bubble.

Ionis Pharmaceuticals, Inc.  (NASDAQ: IONS)

Q3 2018 Earnings Conference Call

Nov. 06, 2018, 11:30 a.m. ET

Ionis Pharmaceuticals Inc

Contents:
  • Prepared Remarks
  • Questions and Answers
  • Call Participants
  • Prepared Remarks:

    Operator

    Good morning, and welcome to the Ionis Pharmaceuticals Third Quarter 2018 financial Results Conference Call. As a reminder, this convoke is being recorded.

    At this time, I would enjoy to turn the convoke over to Wade Walke, Vice President, Investor Relations, to lead off the call. please begin.

    Wade Walke -- Vice President, Investor Relations

    Thank you, Cole. Before they begin, I inspirit everyone to high-tail to the Investor section of the Ionis website to find their press release and the related financial tables, including the reconciliation of the GAAP to pro forma financial measures that they will argue today. They believe pro forma financial results better depict the economics of their commerce and how they manage their business. They own besides posted slides on their website that accompany their discussion today.

    With me on the convoke are today are Stan Crooke, Chairman of the Board and Chief Executive Officer; Beth Hougen, Chief financial Officer; Damien McDevitt, Chief commerce Officer; and Brett Monia, Chief Operating Officer.

    I would enjoy to draw your attention to slide three which contains their forward-looking language statement which we'll be making today, forward-looking language statements which are based on their current expectations and beliefs. These statements are subject to inescapable risks and uncertainties, and their actual results may differ materially. I inspirit you to consult the risk factors discussed in their SEC filings for additional details.

    And with that, I'll turn the convoke over to Stan.

    Stanley T. Crooke -- Chairman of the Board & Chief Executive Officer

    Thanks, Wade, and trustworthy morning, everyone. Thanks for joining us. In the third quarter, they achieved a number of Important milestones, and in the aggregate that results in continued financial strength for the company. We're on track for their third consecutive year of pro forma operating income, and we're doing this while launching TEGSEDI and preparing to launch WAYLIVRA.

    Our solid financial performance results from more sources of revenue including growing SPINRAZA revenue on top of their substantial foundation of R&D revenue from numerous successful partnerships. With the TEGSEDI launch under way, they glance forward to adding commercial revenue from this drug and potentially WAYLIVRA. They await SPINRAZA sales to continue to grow globally, given the positive novel data Biogen reported from the nature study in pre-symptomatic infants.

    We besides await to survey continued growth in key patient segments such as the adult patients in the US which develop up 60% of the SMA population, with only a fraction of those patients now being treated. Positive impact of SPINRAZA has now been recognized with several Prix Galien awards around the world, and was besides recently recognized again by the scientific community with the awarding of the breakthrough prize in life sciences to frank Bennett, their SVP of Research and Head of Neurological Disease Franchise. frank shared this reverence with Dr. Adrian Krainer of glacial Spring Harbor Laboratory.

    The TEGSEDI launch is now under way in multiple countries, and they and their affiliate Akcea are encouraged by the continuing enthusiasm they are seeing from the amyloidosis community for this drug with strong team, the necessary infrastructure and global strategy in place, they are confident in Akcea's aptitude to successfully launch TEGSEDI.

    With WAYLIVRA, they and Akcea are in energetic discussions with EMA, and they continue their conversations for path forward with the FDA. each and every of these review processes are progressing.

    Our EAP program is going well, and they continue to work to bring each and every the patients with FCS, the first-ever treatment of this ultra-rare, debilitating and potentially lethal disease. In the angle 2 study of AKCEA-APO(a)-LRx, the drug demonstrated substantial dose-dependent reductions in a Lp(a) in patients with established cardiovascular disease and elevated Lp(a). They besides observed the auspicious safety and tolerability profile. We're very encouraged by the drug's performance using convenient low-volume monthly doses.

    We and Akcea, along with their confederate Novartis, now own what they need to select a dose and further the drug into a large cardiovascular outcome study to demonstrate the cardiovascular benefits of lowering Lp(a), genetically validated driver cardiovascular disease affecting millions of patients worldwide. angle 2 study of APO(a)-LRx is the largest and the longest study of a LICA drug today, with nearly 300 patients dosed up to 12 months.

    Robust target reduction and auspicious safety and tolerability profile observed in this study adds to their assurance in the potential of LICA drugs to treat a broad scope of diseases with convenient dosing regimens.

    Roche expects to initiate the angle 3 program for IONIS-HTTRx in patients with Huntington disease before the year-end, including a pivotal study and a natural history study. edifice on their successful relationship with Roche, they entered a novel collaboration to the evolution of Ionis factor B LRx. For the treatment of patients with a broad scope of complement-mediated diseases nascence with geographic atrophy, the advanced stage of parch age-related macular degeneration.

    We believe Roche is the birthright confederate to maximize the potential for success of this program, and the substantial flat of participation they retain in the drug's commercial success is another illustration of the strong value of their antisense platform.

    Beyond these Important highlights, we've had numerous other pipeline achievements which not only contribute to their significant financial strength, but more importantly Show that Important novel drugs they are advancing closure to patients who desperately need it. Their focus remains on delivering innovative novel medicines to patients in need, while positioning the company for continued growth.

    I'll now turn the convoke over to Beth.

    Elizabeth L. Hougen -- Senior Vice President, Finance & Chief financial Officer

    Thank you, Stan. trustworthy morning, everyone. They ended the first nine months of 2018 with operating income of $25 million and net income of $51 million, both on a pro forma basis. Their strong financial results were driven by double-digit revenue growth compared to the selfsame epoch in 2017, a nearly threefold extend in commercial revenue from SPINRAZA royalties compared to the first nine months of 2017 together with a substantial foundation of R&D revenue were key factors contributing to their financial performance this year. Additionally, they ended the third quarter with approximately $2 billion in cash.

    With TEGSEDI now launched in multiple countries, and a catalyst-rich next six months, they are positioned for continued financial success. They project their fourth quarter results will be driven by growth in commercial revenue from SPINRAZA royalties as global sales increase. final quarter, they moved into the highest royalty tier which means they rate a greater share of each dollar of SPINRAZA sales. In addition, they await TEGSEDI product sales to contribute to their commercial revenue growth in the fourth quarter.

    We besides project their fourth quarter R&D revenue to extend due to the amortization of the $75 million upfront payment from their novel collaboration with Roche for their FB program. And already this quarter they own earned two milestone payments from AstraZeneca, totaling nearly $30 million for advancing two different programs.

    We are on track to easily meet their guidance of pro forma operating income even while investing in the launch of TEGSEDI and preparing to launch WAYLIVRA. They are projecting to conclude the year with more than $1.8 billion in cash making us cash accretive for six out of the final seven years. They aim to expend their cash to continue to further and expand their pipeline including growing their pipeline of Ionis-owned drugs.

    Worldwide SPINRAZA revenues grew to $468 million driven by quarter-over-quarter and year-over-year revenue growth in the US and even greater revenue growth outside the US. Notably, year-to-date SPINRAZA global revenues surpassed $1 billion in the third quarter. The number of patients being treated with SPINRAZA increased by approximately 20% from the second quarter of 2018 and now nearly 6,000 patients are on SPINRAZA including in the EAP and clinical studies.

    In the US, more than 50% of novel start forms in the third quarter were for adult patients, driving a greater than 20% extend in a number of US adult patients on SPINRAZA compared to the second quarter of 2018. Adult patients depict the largest SMA patients segment accounting for approximately 60% of the prevalent SMA patient population. However, only about 15% of these patients are receiving SPINRAZA today, representing a significant opening for growth.

    Revenue growth outside the US was meaningful as the pace of reimbursement increased particularly in Europe, Asia Pacific and Latin America. They await revenue growth outside the US to continue in the fourth quarter of 2018 as the number of patients on treatment increases. That growth combined with stability in US SPINRAZA revenue in the fourth quarter compared to the third quarter of this year should result in increased royalty revenues from SPINRAZA which are nearly each and every profit.

    R&D revenue for numerous drugs and numerous successful collaborations continues to be a significant component of their total revenue. So far this year, they own earned more than $225 million in R&D revenue, which does not involve the nearly $30 million in milestone payments we've earned so far in the fourth quarter. R&D revenue is a significant and sustainable source of revenue for us, which is why they involve this source of revenue in their valuation model.

    As I discussed final quarter, their R&D revenue consists of four key components: amortization of upfront payments; milestone payments, which represents progress in their existing partnerships; license fees which represents novel transactions and partner's advancing existing program and services they provide to their partners.

    Through the conclude of September, they had recognized $92 million of revenue from amortization and one significant component of this is in the third quarter with $14 million for the first plenary quarter of amortization for their novel Biogen collaboration. They recognized $45 million in the first nine months of this year in milestone payments. Two significant milestone payments in the third quarter were $10 million from AstraZeneca when they initiated a angle 1 study for the first drug in their cardiometabolic collaboration, and $10 million from Biogen when they initiated a angle 1/2 clinical study evaluating their second drug to treat patients with ALS.

    We earned $64 million in R&D revenue during the first nine months of this year from license fees, primarily from AstraZeneca earlier in the year. This does not involve the $12 million license fee they earned from the novel collaboration with PTC to commercialize TEGSEDI and WAYLIVRA in Latin America, which they involve in their commercial revenue. Finally, they earned $25 million from services they provided to their partners, primarily for manufacturing commercial and clinical supplies for them.

    Looking ahead, they await their R&D revenue to grow based on three factors: an extend in the number of partnerships, an extend in partnered program and larger payments as partnered programs advance.

    Let me give you some examples. First, their R&D revenue increases as the number of collaborations they own increases. They recently entered into a second collaboration with Roche. Under this collaboration, they received a $75 million upfront payment. Together with Roche, they will be conducting a angle 2 study in patients with geographic atrophy. Therefore, they will be amortizing the upfront payment over the course of the study nascence in the fourth quarter. They currently own 13 collaborations with large pharmaceutical companies, a number that has more than doubled over the final six years.

    Second, they are progressing more and more programs under their successful collaboration. For each program they advance, they are eligible to rate milestone payments and license fees. They currently own 22 partnered programs, a number that has nearly tripled since 2012. In 2012, they earned $51 million of revenue related to license fees and milestone payments. That's compared to over $135 million in license fees and milestone payments they own earned so far this year.

    Third as their partnered programs advance, the dollar amount they rate for milestone payments and license fees increases, reflecting the extend in value of the advancing program. For example, when they initiated the angle 1/2 study in Huntington's patients, they received a $22 million milestone payment from Roche to befriend fund their cost to conduct the study. When Roche doses the first patient in the pivotal study, they will rate a $35 million milestone payment. Importantly, the $35 million will be each and every profit to us since Roche will be conducting the study.

    In summary, they are sustainably profitable and cash accretive with a manageable expense structure. Their growing commercial revenues together with their substantial foundation of R&D revenue, positions us to finish 2018 in a strong financial position and sets us up for growth in 2019.

    With that, I'll turn the convoke over to Damien to provide a commercial update.

    Damien McDevitt -- Chief commerce Officer

    Great. Thank you, Beth. trustworthy morning, everyone. While it is early days in the TEGSEDI launch, they are pleased with the progress the Akcea team is making to collect TEGSEDI to the patients in need in the US, EU and Canada. While they are not providing sales guidance today, they and Akcea will preserve you updated on how the launch is going.

    TEGSEDI was recently approved in the US with a broad label for treatment of polyneuropathy of hATTR amyloidosis in adults, regardless of stage of disease. Akcea's patient support program has launched and is enrolling patients.

    AKCEA CONNECT was built to support patients through every step of their treatment journey, dedicated nurse case managers steer patients in establishing their monitoring routine as share of the REMS program, befriend navigate insurance coverage options, provide home injection training and more. And together with Akcea's lab service confederate Quest, patients own the option for at-home services.

    Akcea's US domain team is making trustworthy progress in connecting with treating physicians and they are pleased that the first prescriptions own been received. In addition, the TEGSEDI market access team is well along with their efforts to confederate with payors. Importantly, the team is working with those payors who cover the majority of lives in the US to develop the strategy that best fits the goals and the patient population they serve while ensuring that financial barriers did not negatively impact patients in need.

    Akcea's specialty pharmacy Accredo has experienced in supporting this unique need of rare disease communities helping to simplify access to therapy. Today, Accredo has been certified into the REMS program and is ready to assist patients. Accredo has a team of specialty clinicians, pharmacists, and over 600 field-based nurses located throughout the US, who will augment the Akcea connect team of nurse case managers to provide support and address the needs of the hATTR community.

    In Germany, patients are now receiving TEGSEDI in the commercial setting. Akcea's goal is to ensure that patients who need TEGSEDI own access to this. To accomplish this goal, Akcea is working to develop TEGSEDI available to patients across numerous countries in the EU as quickly as possible. Additionally, Akcea Connect is rolling out in the EU to provide the optimal flat of support for patients in each country.

    In Canada, Akcea Connect is in dwelling and they glance forward to delivering the first drug to treat polyneuropathy caused by hATTR amyloidosis to these patients.

    Given TEGSEDI's robust efficacy and simple self-administration, they believe TEGSEDI will be the treatment of choice for people with hATTR and their physicians. Beyond the US, EU and Canada, they and Akcea glance forward to PTC Therapeutics poignant TEGSEDI forward in Latin America. They are besides looking to expand beyond these initial regions as share of their strategy to enable global access to TEGSEDI.

    This weekend, at the International Society for Pharmacoeconomics and Outcomes Research meeting, Akcea is presenting more circumstantial analysis from the neuro TTR study demonstrating TEGSEDI's positive impact on patient's attribute of life. These analyses glance at TEGSEDI's result on patient's aptitude to complete day-to-day activities, as well as positive changes in physical and mental health.

    Now turning to WAYLIVRA. In the EU, their review process is ongoing. In the US and Canada, they aim to work with regulators to validate a path forward. As Akcea continues to work to bring the first ever treatment to patients with FCS, the EAP program is ongoing and Akcea is prepared to launch in the EU as quickly as possible assuming approval. In addition, Akcea is making progress with patient identification with a focus on diagnosis which provides support for their appraise of 3,000 to 5,000 FCS patients worldwide.

    Now, over to Brett, to review key highlights from their pipeline.

    Brett P. Monia -- Chief Operating Officer and Senior Vice President, Translational Medicine

    Thanks, Damien. So, they achieved several additional successes since their second quarter update that I'll now review briefly, and they glance forward to providing a circumstantial update at their Investor Day next month. Biogen recently provided an exciting update from the nurture study in pre-symptomatic infants with SMA. As of May 2018, each and every patients in this study were alive without the need for permanent ventilation, each and every were sitting independently, and nearly each and every were able to walk. And importantly, every participant in this study has continued to develop progress and achieved milestones more consistent with simple development.

    These long-term data provide further evidence that early diagnosis of SMA in treatment with SPINRAZA can fundamentally alter the course of this disease for pre-symptomatic infants and adds to the carcass of evidence supporting SPINRAZA as it would be standard of trust for each and every patients with SMA.

    Shifting gears a bit, in the angle 2 study of AKCEA-APO(a)-LRx, patients with established cardiovascular disease in elevated Lp(a) levels achieved dose-dependent reductions in Lp(a) with most patients in the energetic group attaining levels below the established threshold of risk for cardiovascular disease. Additionally, APO(a)-LRx demonstrated a auspicious safety and tolerability profile consistent with their other LICA drugs. As is well documented, elevated Lp(a) levels is a driver of cardiovascular disease that affects millions of people worldwide. It cannot be controlled with lifestyle modifications such as diet or exercise, and there are no approved therapies that specifically target and reduce Lp(a) levels.

    The Ionis and Akcea team with their confederate Novartis are now preparing for an end-of-Phase 2 meeting with the FDA followed by the potential initiation of a large cardiovascular outcome study which will be designed to demonstrate the cardiovascular benefits of lowering Lp(a) levels in patients with established cardiovascular disease. Novartis, of course, is highly experienced in conducting large CV outcome studies, and they own been actively preparing to initiate the study once they exercise their option.

    And importantly with royalties up to the low 20% range, they retain significant value in the commercial success of the drug. They glance forward to presenting additional data from the angle 2 study this Saturday at AHA and at their Investor Day next month.

    Shifting attention, their confederate AstraZeneca recently reported positive angle 2 data for danvatirsen, their STAT3 inhibitor at this year's ESMO conference. In combination with durvalumab, AstraZeneca's PD-L1 blocking antibody in recurrent metastatic head and neck cancer treatment resulted in 7% of patients achieving a complete tumor response and 23% achieving either a partial or a complete tumor response. This response rate is estimated to be double that of durvalumab alone, based on previous studies in this difficult to treat patient population.

    And their partnership with Roche continues to high-tail well also. Roche announced the study design for the IONIS-HTTRx pivotal program which they aim to initiate before the conclude of the year. Working closely with regulators, Roche has designed a highly innovative pivotal study to generate a robust data set. They collect this Important medicine to people with Huntington's disease as rapidly as possible.

    The program will involve two studies with patients nascence to enroll by early 2019. The first study is a angle 3 study which will be the world's first to measure the result of a drug that will directly reduce the amount of the protein that causes Huntington's disease in patients. This three-year study will evaluate long-term safety and efficacy in up to 660 symptomatic Huntington's disease patients around the globe.

    The second study is a 15-month natural history study in up to 100 symptomatic patients designed to further their understanding of the correlation between changes in novel huntingtin protein and clinical measures.

    As a reminder, IONIS-HTTRx is the first and only drug to demonstrate a substantial lowering of the novel huntingtin protein (inaudible) in clinical profit in patients with Huntington's disease which together support the drug's potential to leisurely or perhaps half disease progression.

    As Stan mentioned, we've recently built upon their successful relationship with Roche with a novel collaboration for the evolution and commercialization of Ionis FPL or actually for the treatment of people with a broad scope of complement-mediated diseases nascence with geographic atrophy, the advanced stage of parch AMD.

    As a reminder, for each product in their pipeline, they survey the commercialization strategy that maximizes the drug's commercial success while optimizing their participation in that success. When partnered with IONIS-FB-LRx requesting for evolution of drugs for renal disease and particularly geographic atrophy is tangled and requires specialized experience.

    Roche has a substantial evolution infrastructure and sustain in developing and commercializing medicines for renal diseases. Furthermore, Roche is prepared to pursue additional complement mediated disease indications well-suited for IONIS-FB-LRx. Importantly, with royalties of up to 20% they participate substantially in the commercial success of this drug. And in the coming months, they glance forward to showing more of the data they own generated from their LICA programs, their other LICA programs, in clinical studies, and publishing the plenary integrated safety database for these LICA drugs which are performing exceptionally well.

    In clinical studies, their LICA drugs had demonstrated increases in potency of 30-fold or greater enabling low volume and less frequent dosing. We've besides reserved trustworthy safety and tolerability potent target production. These results are consistent with those observed in the angle 2 study of their APO(a)-LRx drug in nearly 300 patients treated for up to a year. Finally, they own had many additional achievements since their second quarter update. They completed their enrollment of a angle 2b study of IONIS-FactorXIRx in patients with end-stage renal disease on dialysis and initiated a angle 1 study of the LICA version IONIS-FactorXI-LRx both with data expected in the second half of 2019.

    AstraZeneca initiated a angle 1 study of their first generation 2.5 LICA drug to enter the clinic IONIS-AZ4-2.5-LRx, which is one of the three drugs in evolution under their highly productive cardiometabolic renal disease collaboration with AstraZeneca. And Biogen initiated a angle 1/2 study of IONIS-C9Rx, their second familial ALS drug which is in addition to IONIS-SOD1Rx, which is in a angle 1/2 study in familial ALS and patients with SOD1 mutation with data expected in Q1 2019.

    As shown on this slide, they successfully completed many key milestones this year. In the fourth quarter and into 2019, we're looking forward to numerous Important catalysts including several regulatory decisions, data readouts and study initiations. They besides glance forward to discussing many of these events at their Investor Day in December.

    And now, I will turn the convoke back over to you, Stan.

    Stanley T. Crooke -- Chairman of the Board & Chief Executive Officer

    Thank you, Brett. So, the third quarter was another very strong quarter for the company. They continue to demonstrate the power of the financial model that they built with continuing financial strength even while launching TEGSEDI and preparing the launch of WAYLIVRA. So, they are -- they continue to be substantially profitable and they believe they are positioned for continued growth.

    We believe WAYLIVRA demonstrates a positive benefit/risk profile for patients suffering with FCS with no therapeutic options. Regulatory process continued in the EU, and they are in conversations with the FDA and Canadian authorities as well. Akcea is ready to launch WAYLIVRA as quickly as possible once they own approval in the EU and other territories.

    We own a number of near-term value drivers including plans to initiate at least three pivotal studies before the conclude of the year. These are programs with the potential to change of course lethal genetic diseases, such as Huntington's disease, TTR amyloidosis, as well as diseases that impress millions of patients such as Lp(a) driven cardiovascular disease. They besides own multiple mid-stage programs in a number of therapeutic areas that we're excited about which own the potential to drive longer-term growth. They glance forward to discussing more about these programs as they progress.

    With that, I'll turn the convoke over to Cole to set us up for mp;A. Cole, would you please set us up?

    Questions and Answers:

    Operator

    Certianly. They will now start the question-and-answer session. (Operator Instructions) Their first question comes from Tyler Van Buren with Piper Jaffray. please high-tail ahead with your question.

    Tyler Van Buren -- Piper Jaffray -- Analyst

    Good morning, guys. Thanks for taking my question. I guess, the first one was with respect to the TEGSEDI REMS program, specifically regarding logistics for docs who aren't I guess as chummy with the REMS programs how simple is it going to be for them to sign up? What specifically enact they own to do? How are you guys helping them? And how long could that take? I noticed that some of the questionnaires online are actually quite simple with less than 10 questions, but just wanted to better understand that process.

    Damien McDevitt -- Chief commerce Officer

    Yes. So, thank you for your question, Tyler. So, this is why we've set up Akcea Connect to befriend physicians and patients work through the paperwork associated with the REMS program. So, as you spotted, it's very straightforward going through these paperwork. And to date, there's been no issues. We've had physicians and patients certified through REMS and registered on Akcea Connect.

    Stanley T. Crooke -- Chairman of the Board & Chief Executive Officer

    Just to add to that Tyler, I actually went through the process myself, and so there was a lot of trouble at reducing the affliction everywhere on the patient, on the physician and the physician's office. And so I feel very, very uncomfortable with how simple it is to enroll in the program that Akcea has build together. I Think it's quite an exciting further in managing these processes.

    Tyler Van Buren -- Piper Jaffray -- Analyst

    That's great. Are you able to squawk how many doctors are certified on the REMS or how many patients are on the REMS?

    Damien McDevitt -- Chief commerce Officer

    No, we're not providing numbers. They own had patients and physicians certified to-date, but we're not giving out the exact numbers at this point.

    Stanley T. Crooke -- Chairman of the Board & Chief Executive Officer

    We're encouraged by what received. We're encouraged by what received.

    Tyler Van Buren -- Piper Jaffray -- Analyst

    Okay. And the second question was with respect to the platelet monitoring. I guess, I'm assuming that the samples need to be taken by a nurse and that the patient can't enact it themselves, or maybe you can correct me if I'm wrong, but specifically and logistically, how will it happen? How long will it take? And if someone is on a commerce trip how would you collect their platelet levels monitored on a weekly basis?

    Damien McDevitt -- Chief commerce Officer

    So, the patient -- the platelet monitoring will happen, the blood draws will be done at home, and with nurses, and so does that help.

    Stanley T. Crooke -- Chairman of the Board & Chief Executive Officer

    So, platelet monitoring is designed so it will be as convenient as possible. We'll high-tail where the patient wants us to go. The patient is near a lab and they prefer going in and getting their blood drawn there. distinguished if they are traveling, why, of course, there are clinical laboratories everywhere, (inaudible) so that the patient can high-tail there and collect the job done. And of course we're providing the opportunities to own the platelets determined or blood drawn in, in the home as well. At least, once a week, it's over in a matter of just a yoke of minutes. It's rapid easy. Certainly, speaking for myself, I would rather enact that and high-tail to an infusion center and spend a day getting an IV infusion.

    Tyler Van Buren -- Piper Jaffray -- Analyst

    Yes. And that makes sense. I guess if you're having nurses high-tail to the patient's home or if they're on a commerce trip and wherever location they are, don't you guys own to own a lot of nurses on staff or be plugged into some large network? Just I guess curious to hear a petite bit about that.

    Damien McDevitt -- Chief commerce Officer

    Yes. So, when they are plugged into the large network and through Accredo, there are 600 nurses on staff throughout the US. So that's fairly large network available.

    Stanley T. Crooke -- Chairman of the Board & Chief Executive Officer

    And Quest. Of course, they own a partnership with Quest, so that there's a lab. It's not Starbucks, but it's almost Starbucks, except the lines are shorter.

    Tyler Van Buren -- Piper Jaffray -- Analyst

    Great. Thanks a lot for taking the questions.

    Stanley T. Crooke -- Chairman of the Board & Chief Executive Officer

    You bet.

    Operator

    And their next question comes from Paul Matteis with Stifel. please high-tail ahead with your question.

    Ben Burnett -- Stifel -- Analyst

    Hi. Thank you. This is Ben Burnett on for Paul Matisse. Just a question on the SOD1 program, the upcoming readout here. Can you argue what flat of knockdown you would constitute as sufficient as supportive of advancing the program? And then I guess secondly, are you able to speak to the flat of enrollment to the extension study? And I guess, can you just remind us of the regulatory path forward for this assuming positive data in 2019? Thank you.

    Brett P. Monia -- Chief Operating Officer and Senior Vice President, Translational Medicine

    Yes. This is Brett. I will purchase that convoke -- that question. So, as I Think you inferred, they can measure SOD1 levels. They validated SOD1 levels in the CSF much enjoy they did for the Huntington program, where they were able to demonstrate market reductions in the CSF for Huntington. So that will be share of the clinical study. It's a three-month study in patients with symptomatic ALS with SOD1 mutations. And based on a pre-clinical data, they can -- that reductions on the order of 30% to 50% much enjoy Huntington own shown significant profit in animal models of SOD1 ALS. In fact those types of reductions own shown complete halting of disease progression in SOD1 animal models.

    Regarding the study, the study is enrolled. And we're looking at data readout in the first quarter of next year. And as for regulatory path, it's difficult to say, how they survey the data. But as I mentioned, the study design is very similar to the Huntington study. And as you know, the Huntington study went from angle 1 to pivotal angle 3 study. So, it's not outside the wrong possibility that based on the data that comes out, Biogen would high-tail in that direction.

    Ben Burnett -- Stifel -- Analyst

    Thanks Brett.

    Wade Walke -- Vice President, Investor Relations

    Next question please.

    Operator

    And their next question comes from Chad Messer with Needham & Company. please high-tail ahead with your question.

    Chad Messer -- Needham & Company -- Analyst

    Great. Thanks. Thanks for taking my question. I own one on danvatirsen, the STAT3 program. What can they await from that next maybe in terms of other indications? And any concept when that might relate the ranks of angle 3 along with some of the other programs?

    Brett P. Monia -- Chief Operating Officer and Senior Vice President, Translational Medicine

    Thanks, Chad. So, thanks for the question. Yes, their immuno-oncology program -- their oncology program in universal is really showing a lot of distinguished potential. Their STAT3 leads the way. It was their first-generation 2.5 molecule to enter the clinic. And we've recently with AstraZeneca recently reported very encouraging results as I highlighted in the script in the presentation they just gave in patients with refractory head and neck cancer in combination with durvalumab. That study -- that drug in that combination has besides now started a steady non-small cell lung cancer, so that's another indication to your question, and bladder cancer. And AstraZeneca is exploring other oncology indications produced for this program.

    AstraZeneca is collecting more and more data in this study, in the second line refractory study, as well as in first line head and neck cancer patients in combination with durvalumab. And over the next few months, they're planning to develop a decision on the next stage of evolution for the program in the head and neck cancer which could certainly be a pivotal study.

    Chad Messer -- Needham & Company -- Analyst

    Thanks, Brett.

    Operator

    And their next question comes from Gena Wang with Barclays. please high-tail ahead with your question.

    Gena Wang -- Barclays -- Analyst

    Thank you for taking my questions. One question regarding SPINRAZA, I know the World Muscle, nurture data was very impressive. Just wondering what will be the next step to expand label to the pre-symptomatic patients? And then a very quick question regarding the WAYLIVRA, any aim for the FDA regulatory path for the next step?

    Stanley T. Crooke -- Chairman of the Board & Chief Executive Officer

    Thanks. The SPINRAZA label supports administration of SPINRAZA to patients of any sort with SMA. And certainly more and more babies are being treated presymptomatically because the data are so overwhelmingly positive. So that's happening as they speak.

    Damien McDevitt -- Chief commerce Officer

    And, of course, just to add to that Stan, as you know Gena, the newborn screening has incorporated now officially nationally SMN2 as a genetic measurement in the newborn screen panel to identify the patients that are presymptomatic that will develop SMA. And now that's becoming incorporated into a statewide system and nationally as well. So each and every this bodes very well for treating more and more patients presymptomatically both the genetic testing as well as the data, the nurture data that was presented in World Muscle.

    Stanley T. Crooke -- Chairman of the Board & Chief Executive Officer

    The other thing that's sort of been forgotten, but it's tremendously impressive to me is that it's not just in the nurture study that they survey would continue to -- treatment patients continue to collect better and better. We're seeing the selfsame sort of behavior in less severe infants and infants that are treated asymptomatically and we're seeing it in the type two and the adult patients as well. So, today SPINRAZA has delivered incredible value. And the longer they treat, the better it is for essentially each and every the patient types that own been treated with SPINRAZA. So, it looks quite exciting.

    Wade Walke -- Vice President, Investor Relations

    Next question.

    Operator

    Our next question comes from Jessica Fye with JP Morgan. please high-tail ahead with your question.

    Jessica Fye -- JPMorgan -- Analyst

    Great, and thanks for taking my questions. Can you befriend us Think about when they could survey extension data from the Huntington's angle 1/2 trial? I Think clinical trials enjoy I've said it's 14 months of treatment with completion in December of 2019. Is it possible they could survey incremental update sooner given that it's open label? besides can you talk to the dose levels and dosing frequency in that extension trial?

    Brett P. Monia -- Chief Operating Officer and Senior Vice President, Translational Medicine

    Sure, Jess. Roche is not -- well the open label extension study is going very well. each and every the patients are obviously enrolled into the study, and they're in the study. They are continuing to be treated, and it's going well as I said. Roche has been very transparent, and has worked very closely with patient advocacy, patients, doctors, physicians, and has been very transparent in the information they've provided. They haven't said specifically when and in what cadence they're going to actually share data from the open label extension, but they believe that they'll be sharing data over the course of 2019 because it's so Important to the patient community to share that data and know how the program is going. The dosing is the selfsame as it was in angle 1/2 which is monthly dosing, and they're administering the top dose and that was from the angle 2 study.

    Jessica Fye -- JPMorgan -- Analyst

    Okay. And apologies, if I missed this, but for the two-year angle 3s for that product, what specifically will be the primary clinical efficacy endpoint?

    Brett P. Monia -- Chief Operating Officer and Senior Vice President, Translational Medicine

    So the clinical endpoints are now -- own been disclosed by Roche. They're going to involve both cognitive measures, motor role measures, autonomic (ph) measures of neurological functions as well as MRI scans of brain size, and those sorts of things, quality-of-life measures. It's a composite scoring system that we're using in US and EU. It is slightly different in US and EU, and but it's now been fully vetted through the FDA, the EMA and it's been posted.

    Jessica Fye -- JPMorgan -- Analyst

    Okay. Great. And final one for me is just Novartis made some comments yesterday that they are not especially focused on combining splice modulators with gene therapy and SMA. So just curious as the leader in SMA what was your reaction to that view?

    Stanley T. Crooke -- Chairman of the Board & Chief Executive Officer

    Well, they are leaders in SMA, and they enact Think that there are opportunities in the future to expend a variety of agents in combination. Whether a gene therapy agent would add any value to SPINRAZA given the results that they own is difficult for me to know today. So, we're watching the progression of the gene therapy as well as small molecule. And if there appears to be some spot in which SPINRAZA doesn't bring sort of remarkable value, I'm sure, that Biogen and others will glance at combinations. There's nothing to preclude any combination with any of the drugs that are in evolution that we're sensible of.

    Jessica Fye -- JPMorgan -- Analyst

    Okay, great. Thank you.

    Operator

    And their next question comes from Jim Birchenough with Wells Fargo. please high-tail ahead with your question. Mr. Birchenough (multiple speakers).

    Yanan Zhu -- Wells Fargo -- Analyst

    Yeah. Sorry about that. Thanks. This is Yanan in for Jim. So first question regarding SPINRAZA revenues, could you picture the driver for the growth? Is it patient number or some other factors such as change in the early patients edifice schedule versus longer intervals in previously enrolled patients? So, any color on that?

    Stanley T. Crooke -- Chairman of the Board & Chief Executive Officer

    It's patient numbers. There hasn't been any change in dosing schedule. So what's happening is that more patients are being treated, and the patients that own been treated are continuing to be treated. So it's -- I Think just correlates with benefit. More patients are being treated and more patients are being treated longer.

    Yanan Zhu -- Wells Fargo -- Analyst

    Got it. And you described an extend in adult patients. Would you be able to comment whether the pediatric patients whether that portion of the market is stable? Yeah.

    Stanley T. Crooke -- Chairman of the Board & Chief Executive Officer

    It continues to grow.

    Yanan Zhu -- Wells Fargo -- Analyst

    Got it. And you were just talking about the combinations -- potential combination the possibility with gene therapy between SPINRAZA and gene therapy. I thought Novartis mentioned a price tag of $4 million to $5 million for their gene -- potentially for their gene therapy. How does that -- what's your view on that, and how might that impact the aptitude to combine the two drugs?

    Damien McDevitt -- Chief commerce Officer

    Well, I Think it's early days. And I Think I'll let Novartis argue their pricing and its impact on whether patients of sort uses drug, and whether -- would develop sense to combine it. At that price obviously any combination would own to Show an extraordinary profit compared to SPINRAZA. That's going to be very difficult to enact given the fact that the vast majority of presymptomatic patients who were treated are developing enjoy simple children. How enact you enact better than that?

    Yanan Zhu -- Wells Fargo -- Analyst

    Got it. And the final question on the Huntington's disease trial -- angle 3 trial design by Roche. Would you be able to comment on whether the angle 3 study the 660-patient study would that be a controlled or uncontrolled study?

    Damien McDevitt -- Chief commerce Officer

    It's 660 and it's a controlled study, yes.

    Yanan Zhu -- Wells Fargo -- Analyst

    Got it. Thank you.

    Operator

    And their next question comes from Vincent Chen with Bernstein. please high-tail ahead with your question.

    Vincent Chen -- Bernstein -- Analyst

    Great. Thank you very much for taking the question. So, I guess, one question about SPINRAZA and sort of the future of the SMA market, how are you and your partners with Biogen thinking about defending against Roche's oral compound in SMA for illustration whether that's next-generation agents with profiles edifice up with the SPINRAZA and trying to demonstrate areas of potential superiority whether with SPINRAZA or follow-on potentially using the novel biomarkers, et cetera? Could you just provide us with more color on how you Think about a market defense strategy here?

    Stanley T. Crooke -- Chairman of the Board & Chief Executive Officer

    Well, I Think the first order of commerce is to continue to learn more about SPINRAZA. And today the more they learn the better the drug appears to be in each and every patients. Second, of course, they are collaborating with Biogen to glance at a novel -- various follow-ons to SPINRAZA that might own lower doses or might own less frequent dosing. I Think it's -- what I Think needs to betide now, before they comment on whether oral agents might be used, might be used in combination and how they might be used is one to watch how SPINRAZA does over the next year. They continue to watch that. And then second, to evaluate these -- the clinical trials that are in progress both in terms of profit and safety. I think, there's not very much yet really know about the small molecule drugs and we're looking forward to seeing the data.

    Vincent Chen -- Bernstein -- Analyst

    Thank you.

    Operator

    And their next question comes from Ritu Baral from Cowen. please high-tail ahead with your question.

    Ritu Baral -- Cowen & Company -- Analyst

    Hi, guys. Thanks for taking the question. Going back to the Huntington's endpoint, the angle 3 endpoint that they were talking about before, I Think you guys mentioned, it was a composite cognitive motor functions autonomic, MRI volume and attribute of life. How are those weighted within the composite? Is there any requirement for one factor to Show inescapable threshold result for that composite endpoint to be positive? How does that primary endpoint work?

    Damien McDevitt -- Chief commerce Officer

    Yes. Ritu, they will own to -- I don't own those details in front of us on how the various components to the composite score are weighted. Why don't they collect back to you on that?

    Ritu Baral -- Cowen & Company -- Analyst

    Sure. And then a quick follow-up on WAYLIVRA in Europe. Can you remind us where you are on that process? own you received enjoy the 120-day questions as they progressed -- as there own been progress made between 120 and 180 days? Any details that you can share?

    Damien McDevitt -- Chief commerce Officer

    We're late in the process. They enact -- we've had a number of meetings and conversations and responses to a variety of questions 120-day and others. So we're late in the process and we're looking forward to bring it to a conclusion here in the next quarter.

    Ritu Baral -- Cowen & Company -- Analyst

    Got it. And apologies if I just wasn't writing lickety-split enough here. You enact own commercial patients on TEGSEDI. I know you own German commercial patients treated. enact you own US commercial patients treatment already started? Or is that going to be imminent given accretive just got it licensed?

    Damien McDevitt -- Chief commerce Officer

    Yes. Thanks, Ritu. They own patients and physicians that are certified through REMS and registered on Akcea Connect. And they own specialties -- their specialty pharmacy certified through REMS as well and is up and running. And they own meetings with physicians and their teams and they received the first set of scripts. That's where they are today.

    Ritu Baral -- Cowen & Company -- Analyst

    Got it. Okay. That's helpful. And then I guess final question is -- sorry, the conclude of angle 2 meetings that you and Novartis will own on Lp(a), given that we're each and every expecting just sort of a really simple vanilla tedious endpoint angle 3. Are there other topics to argue any aspect of the compound or Lp(a) that are worth noting outside just the simple relatively tedious angle 3 time?

    Brett P. Monia -- Chief Operating Officer and Senior Vice President, Translational Medicine

    That's the first time I've heard an outcome study described as relatively boring, but OK. We're kindhearted of excited about it, and I think, I'll just leave it there. It's a trustworthy question, but it's a petite more circumstantial than I Think would be commandeer to high-tail into here. I'm sure that once they own the meeting that they own to argue each and every that in a petite more detail. I will inspirit everyone to develop the late-breaker that's coming this Saturday that Sam Tsimikas is presenting. We're really, really excited about the data they own to share both in terms of the potency of the agent as well as the safety tolerability. And so they glance forward to being able to share much more circumstantial data with the community.

    Ritu Baral -- Cowen & Company -- Analyst

    Got it. Thanks for taking each and every the questions.

    Brett P. Monia -- Chief Operating Officer and Senior Vice President, Translational Medicine

    You bet.

    Operator

    And their next question comes from I-Eh Jen with Laidlaw & Company. please high-tail ahead with your question.

    Yale Jen -- Laidlaw & Company -- Analyst

    Thanks a lot for taking the questions. And I Think a lot own been answered, I've got two here. The first one is that for the NASH you own two data releases later both regarding the NASH. One is the DGAT2 and the other is the ANGPTL3. Could you differentiate the specific indications that these two drop may own a target.

    Stanley T. Crooke -- Chairman of the Board & Chief Executive Officer

    Yes, that is a very enchanting question. They own quite a pipeline of different agents focused on either the lipid component of NASH or the fibrotic component of NASH or each and every the above. The way I Think of DGAT2 is that it's highly specific to reduce triglycerides in the liver. And so they Think of it as a very specific reagent that should own a towering substantial profit in liver fab without any of the sort of issues that trying some of the other drugs such as increasing LDL and that sort of thing. With ANGPTL3 that's a universal dyslipidemia agent in their mind. They know that it lowers LDL, they know that it lowers triglycerides. They know that it lowers ApoB100.

    And so in the study that we're conducting we're asking you the question, does that translate to a significant reduction in triglycerides in the liver? And then we'll glance at the composite profit of that drug grams. It could be a candidate for expend as a universal agent to reduce triglycerides in people with moderately elevated triglycerides. It could be used to treat patients with a broad scope of dyslipidemias and it could be used to treat NASH. So if you Think about DGAT2, is a very selective and specific liver triglyceride drug primarily, and ANGPTL3 is more a universal dyslipidemia drug with NASH as opening among the several that they will pursue. That will be the way I Think about it.

    Yale Jen -- Laidlaw & Company -- Analyst

    So would that be -- may be in more specific to squawk that was targeting to a early disease process of the NASH, but not necessarily into the fibrosis progress into the fibrosis condition?

    Stanley T. Crooke -- Chairman of the Board & Chief Executive Officer

    Well, that's correct. These two drugs are focused on the lipid which is the driver of the disease, and so they believe that as they lower the liver triglycerides, they will impress the progression of the disease and reduce the progression of disease. They own other agents that are coming that are focused on the fibrotic share of the process as well. So what they are going to be doing over the next petite bit, is looking at the data that they own in each of these drugs and sliding down for the best patient population for each of the drug. They Think this share of -- this component of their pipeline is really quite exciting.

    Yale Jen -- Laidlaw & Company -- Analyst

    Maybe one more question --

    Stanley T. Crooke -- Chairman of the Board & Chief Executive Officer

    And it besides demonstrates the power of antigens. They can create selective drugs to target different targets, different parts of pathways, different parts of causes of these tangled multi-factor diseases. And then let the data speak and command us where they should be positioned each one of their opportunities.

    Yale Jen -- Laidlaw & Company -- Analyst

    Yes, maybe one more question regarding the Huntington disease. You squawk there's two studies and the first study mainly focus on the reduction of the Huntington proteins. And -- but that study you're besides monitoring some kindhearted of symptomatic differences over times and maybe own some sort of readout even before the second study is fully enrolled. Is that the aim or does that.

    Stanley T. Crooke -- Chairman of the Board & Chief Executive Officer

    No, that's correct. That's the open label extension and they are encouraged by what we've been seeing. And as Brett said, they enact believe that Roche will be providing updates on the progress in that study in 2019 although I can't speak for Roche in more detail.

    Yale Jen -- Laidlaw & Company -- Analyst

    And does the drug own two different -- there is a cohort A and B is at different flat of the -- as that tend to be administrated.

    Stanley T. Crooke -- Chairman of the Board & Chief Executive Officer

    I Think the open label extension is going simply at the highest dose.

    Damien McDevitt -- Chief commerce Officer

    Correct.

    Yale Jen -- Laidlaw & Company -- Analyst

    Okay. Great. Thanks a lot. I appreciate it.

    Stanley T. Crooke -- Chairman of the Board & Chief Executive Officer

    You bet.

    Operator

    And their next question comes from David Lebowitz with Morgan Stanley. please high-tail ahead with your question.

    David Lebowitz -- Morgan Stanley -- Analyst

    Thank you very much for taking my question. With respect to TEGSEDI reimbursement, could you hasten us through I guess what types of -- what pieces of information payers in the early hasten own requested regarding patients and discovering the reimbursement process understanding that you haven't actually finished the whole process yet with patients?

    And then beyond that, what is your expectation for turnaround time from when a patient initially meets with the doctor regarding potentially getting prescribed TEGSEDI to nascence the REMS process and eventually becoming paid and reimbursed it on drug?

    Stanley T. Crooke -- Chairman of the Board & Chief Executive Officer

    I'm going to suggest that you address those questions primarily to Akcea. There are a lot of detail in the process. I can give you my sense of what I understand. I know that their colleagues at Akcea own met with many payors before and after launch. And the focus of payors was sort of where you would await it to be in the profit versus the cost. And I understand that those conversations own gone extremely well.

    And the Akcea Connect program is really a very robust highly focused on getting patients into treatment with the easiest process and the shortest time possible, and facilitating the practitioners' entry into the treating of the patient and taking advantage and taking trust of the time of the practitioner who manage these patients.

    So, it's short, but I can't command you the exact time between start and finish. And I suspect that they really won't know for a while just how it's each and every going to work until they did a lot more experience. And I'm sure as they gain experience, we'll be able to be even shorten it further.

    David Lebowitz -- Morgan Stanley -- Analyst

    Thank you very much for taking my question.

    Stanley T. Crooke -- Chairman of the Board & Chief Executive Officer

    Yes. If that is the final question, so I'd enjoy to bring the convoke to a close. Once again, thanks everyone for joining us today. I very much appreciate your interest and the questions that you've asked. They inspirit you to stay tuned for APO(a)-LRx deal that will be presented in more detail this Saturday at AHA. And they glance forward to seeing you at their Investor Day in novel York in which we'll own the opening to provide a significant -- significantly greater update on essentially everything that we're doing.

    What they are really excited about is that we're progressing to commercializing their two novel drugs while SPINRAZA continues to effect well, advancing their pipeline continuing to further the technology. We're witnessing the improvements in the technology being manifested in the performance of their drugs across the board, and we're doing each and every that while we're growing operating profits and we're cash accretive. They Think that's an exciting story, and we're looking forward to telling it in more detail in their Investor Day. Thanks very much.

    Operator

    The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.

    Duration: 61 minutes

    Call participants:

    Wade Walke -- Vice President, Investor Relations

    Stanley T. Crooke -- Chairman of the Board & Chief Executive Officer

    Elizabeth L. Hougen -- Senior Vice President, Finance & Chief financial Officer

    Damien McDevitt -- Chief commerce Officer

    Brett P. Monia -- Chief Operating Officer and Senior Vice President, Translational Medicine

    Tyler Van Buren -- Piper Jaffray -- Analyst

    Ben Burnett -- Stifel -- Analyst

    Chad Messer -- Needham & Company -- Analyst

    Gena Wang -- Barclays -- Analyst

    Jessica Fye -- JPMorgan -- Analyst

    Yanan Zhu -- Wells Fargo -- Analyst

    Vincent Chen -- Bernstein -- Analyst

    Ritu Baral -- Cowen & Company -- Analyst

    Yale Jen -- Laidlaw & Company -- Analyst

    David Lebowitz -- Morgan Stanley -- Analyst

    More IONS analysis

    Transcript powered by AlphaStreet

    This article is a transcript of this conference convoke produced for The Motley Fool. While they strive for their absurd Best, there may be errors, omissions, or inaccuracies in this transcript. As with each and every their articles, The Motley Fool does not assume any responsibility for your expend of this content, and they strongly inspirit you to enact your own research, including listening to the convoke yourself and reading the company's SEC filings. please survey their Terms and Conditions for additional details, including their Obligatory Capitalized Disclaimers of Liability.

    SPONSORED: 10 stocks they enjoy better than Ionis Pharmaceuticals

    When investing geniuses David and Tom Gardner own a stock tip, it can pay to listen. After all, the newsletter they own hasten for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*

    David and Tom just revealed what they believe are the 10 best stocks for investors to buy birthright now... and Ionis Pharmaceuticals wasn't one of them! That's birthright -- they Think these 10 stocks are even better buys.

    Click here to learn about these picks!

    *Stock Advisor returns as of August 6, 2018

    Motley Fool Transcribers has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Ionis Pharmaceuticals. The Motley Fool has a disclosure policy.


    District 181 Welcomes novel Staff Members for 2012-13 | killexams.com real questions and Pass4sure dumps

    This post was contributed by a community member.

    New Administrators (alphabetical by final name)

     Christine Cagney (Principal, Walker School) has a B.S. in commerce Administration from Fordham University, as well as an M.A. in Teaching in Special Education and an M.Ed. in Administration and Supervision, both from National Louis University. Ms. Cagney was an coadjutant Principal at Hunting Ridge Elementary School in Palatine Community Consolidated School District 15 for two years and was a special education teacher in Woodridge School District 68 for four years.

    Deborah Doyle (Pupil Services Administrator) has 16 years of sustain in schools. Ms. Doyle worked for eight years in Naperville Community Unit School District 203 as an coadjutant Director for Pupil Services and as an coadjutant Principal, one year in Birmingham Schools as a Special Education Department Chair, two years in Clarkston Community Schools as a Supervisor of Student Support Services and a middle school special education teacher, one year as a special education teacher in Downers Grove, and four years as a special education teacher in Lockport. She earned a B.S. in Special Education from the University of Wisconsin - Oshkosh and an M.A. from Governors State University.

    Gary Frisch, CPA (Assistant Superintendent for Business) comes to District 181 with 25 years of sustain in school commerce management, including 19 years as the chief school commerce official. Mr. Frisch most recently worked at Barrington Community Unit School District 220 and in Glenbard Township towering School District 87. He serves as an adjunct professor at Aurora University and Concordia University, teaching graduate courses in school finance and school ethics. Mr. Frisch earned his B.S. in commerce Administration from Illinois State University – simple and his M.S. in School commerce Management from Northern Illinois University – DeKalb. Mr. Frisch has a Type 75 certificate and Chief School commerce Official endorsement.

    Casey Godfrey (Principal, The Lane) had been principal of Fairmount Elementary School in Francis Howell School District in Missouri for the past three years. Prior to that, Mr. Godfrey worked in the Lincoln County R-III School District in Missouri, where he was a teacher and later a principal of Hawk Point Elementary. He began his career in education as a 4th and 5th grade teacher at William Cappel Elementary. He has an M.Ed. from Lindenwood University in Missouri, in addition to a B.S. in Elementary Education from Murray State University in Kentucky.

    Bridget McGuiggan, APR (Director of Communications) served as the Community Relations Coordinator at Orland School District 135 for six years before joining District 181 in July. Prior to working in Orland 135, she was the Coordinator of Marketing and Public Relations at Queen of Peace towering School, her alma mater. Her B.S. is in Mass Communications and Marketing, earned from Saint Joseph's College in Indiana. Additionally, she has earned Accreditation in Public Relations (APR) and is Past President of the Illinois Chapter of the National School Public Relations Association.

    Dr. Kurt Schneider (Assistant Superintendent for Learning (Pupil Services)) comes to District 181 from Wisconsin, where he had been the Co-Administrator of Teaching and Learning, Director of Student Services, for the Stoughton zone School District for the past eight years. Dr. Schneider began his career as a towering school special education teacher at Madison East towering School. He has served as an adjunct university instructor for graduate and undergraduate courses in the Departments of Educational Leadership and Policy Analysis and Rehabilitation Psychology and Special Education at the University of Wisconsin-Madison, and besides at Edgewood College in Madison. He earned a doctorate in educational administration, a master's degree in special education and a bachelor's degree in special education, each and every from the University of Wisconsin - Madison.

    New Teachers, Interventionists, Therapists (Alpha by Last)

     Kristi Awtry (Resource, HMS (.5FTE)) returns to District 181 this year after serving as a long-term substitute. Her sustain includes work at Elm, Oak, and HMS, in addition to four years of sustain in the Oklahoma zone with Pre-K, 1st grade, and 7th and 8th grade students. She has a B.S. in Elementary Education from the University of Central Oklahoma and has completed coursework in the special education domain and earned a Learning behavior Specialist I endorsement.

    Karen Berman (ECE, Sp. Ed., Oak) is no stranger to Early Childhood Education, with sustain in Early Childhood programs in both Waukegan and Palos Heights schools. She has a B.S. in Early Childhood Education and an M.Ed. in Early Childhood Special Education, both from the University of Illinois at Urbana-Champaign. Ms. Berman has besides earned a Learning behavior Specialist I endorsement.

    Kathryn Cox (Science / Language Arts, Grade 6, CHMS) holds a B.A. in Elementary Education with a minor in Biology from Elmhurst College, where she graduated with Highest Honors and was a member of the Kappa Delta Pi reverence Society. Ms. Cox has seven years of sustain in schools, including one year with Keeneyville Elementary School District 20 in Roselle and six years with District 181 at both CHMS and HMS.

    Jessica Czerniuk (P.E., Madison (.94FTE)) will bring sustain in Physical Education from two previous districts when she comes to Madison. Ms. Czerniuk was a P.E. teacher in South Holland School District 151 and Maercker School District 60. She has a B.A. in Kinesiology and Physical Education from Northern Illinois University and an M.A. in Curriculum and Instruction from Olivet Nazarene University.

    Jennifer Duffy (Assistive Technology, District-wide (.5FTE)) will spend time in each and every District 181 schools through her role in Assistive Technology. She earned a B.A. in Special Education from Northern Illinois University and has completed coursework related to brain-based learning and technology for students with disabilities. Ms. Duffy previously worked for the Kendall County Special Education Cooperative and in Indian Prairie School District 204, serving students in Aurora and Naperville. Ms. Duffy is currently a Literacy Consultant for Gretchen Courtney & Associates, Ltd.

    Erin Eder (School Psychologist, District-wide) holds a B.S. in Psychology from the University of Illinois Urbana-Champaign and an Educational Specialist degree in School Psychology from National-Louis University. Her previous work sustain includes three years as a school psychologist with the Southern Will County Cooperative for Special Education.

    Jean Fitzgerald (Art / Computer Graphics / MS Skills, CHMS (.5FTE)) is a winner of the 2011 Hillbrunner Artists engage Fellowship through the School of the craft Institute of Chicago, where she earned an M.A. in teaching. Ms. Fitzgerald besides holds a B.F.A. in Painting from the University of Michigan.

    Laura Ghera (Music, Monroe) comes to District 181 with sustain as a chorus and universal music teacher, with time spent in Butler School District 53, Geneva Community Unit School District 304, and Lisle Community School District 202. She besides taught e-Learning for District 53. Mrs. Ghera earned a B.A. in Vocal Performance and Hispanic Studies from Illinois Wesleyan University and an M.M.Ed. from the VanderCook College of Music.

    Karen C. Johnson (Balanced Literacy Coach, District-wide) will work with students at each and every grade levels through her role as a Balanced Literacy coach. With a B.A. from Northeastern Illinois University, an M.A. in Reading from National Louis University, a Learning behavior Specialist endorsement, and training in Reading Recovery, Ms. Johnson is ready to succeed in District 181. Her sustain includes work in Naperville Community Unit School District 203 and Plainfield Community Consolidated District 202, where she earned an award from the Coordination of Administration and Parents Groups for Educational Efficiency.

    Dr. Kathy Kula (School Psychologist, District-wide) holds a B.S. in Psychology and Sociology from the University of Illinois at Urbana-Champaign and an M.A.T. in Elementary Education from Dominican University, as well as an M.Ed. in School Psychology and a Ph.D. in School Psychology, both from Loyola University Chicago. Dr. Kula's previous work sustain includes an internship with Park Ridge-Niles School District 64, a specialty practicum at Edwin G. Foreman towering School, and a practicum at Morton West towering School. She besides taught 6th and 7th grade math, science, and social studies at the Chicago International Charter School in Washington Park.

    Justine Legner (3rd Grade, Prospect) taught math and reading at District 181's The Lane and holds a B.A. in K-9 Elementary Education from North Central College.

    Cherise Madden (Resource, Elm (.5FTE)) earned a B.A. in Elementary Education from Elmhurst College and an M.A. Reading Specialist degree from National Louis University. Ms. Madden besides holds a Certificate of Advanced Instruction in Special Education. Her background includes teaching 1st grade in Melrose Park, 2nd and 3rd grade in Elmwood Park, and kindergarten, 1st grade, and 2nd grade for St. Giles School in Oak Park.

    Juliette Nardulli (Resource, Oak) is currently working toward an M.A. Reading Specialist degree from Concordia University. Mrs. Nardulli earned a B.A. in Elementary Education from Benedictine University and holds a Learning behavior Specialist endorsement from Roosevelt University. Mrs. Nardulli's sustain includes teaching 1st grade and kindergarden at Kingswood Academy in Darien. She besides taught 4th grade at Noonan Academy in Mokena. Mrs. Nardulli served as an instructional aid at Oak and as a long-term substitute in Monroe and Madison Schools in District 181 in the 2011-12 school year.

    Meg Neubauer (Social Worker, Madison) earned both a Bachelor's and Master's degree in Social Work from Loyola University, where she besides earned a B.A. in Sociology. Ms. Neubauer holds a Type 73 certificate, as well. She has been an Early Childhood Social Worker in McHenry School District 15 and in the LaGrange zone Department of Special Education (LADSE).

    Margo Rodenbostel (Social Studies, CHMS (.33FTE)) worked in District 181 for three years before returning now as a 6th grade social studies teacher at CHMS. She has a B.A. in International Relations from the University of Wisconsin – Madison and an M.A. in Education from DePaul University.

    Ele Santini (Social Worker, CHMS) has a B.A. and an M.A. in Social Work from the University of Illinois at Chicago, in addition to a Type 73 certificate. She is a Licensed Clinical Social Worker and Accredited Case Manager, as well. Ms. Santini served as a social worker for 11 years in a medical setting and besides interned as a social worker at HMS.

    Chris Taylor (Intermediate (3-5), Monroe) has an M.A. in Teaching with Certification from Aurora University and earned a Learning behavior Specialist I endorsement. Mr. Taylor worked for two years in Elmhurst Community Unit School District 205 as a 5th grade teacher. He besides taught 5th grade in Plainfield Community Consolidated School District 202.

    Lindsay Wagner (4th Grade, Oak) comes to District 181 from the Colorado area, where she taught 4th and 5th grade literacy. She besides served as a long-term substitute for 4th grade at Oak in District 181 and besides in 1st and 4th grades in Western Springs District 101. Her previous work sustain besides includes seven years in advertising. Mrs. Wagner earned a B.A. in Journalism and Mass Communications from the University of Iowa and has completed graduate work towards an elementary license and an elementary literacy leadership endorsement at the University of Colorado at Denver.

    Patricia Ward (SLP for ECE, Oak) has an M.S. in Speech-Pathology from Marquette University and is certified in Neurodevelopmental Treatment. She is presently studying for Board Certified behavior Analyst certification in Applied Behavioral Analysis at the Chicago School of Professional Psychology. Ms. Ward previously worked for LaRabida Children's Hospital, Children's Memorial Hospital, and a private drill in Orland Park, in addition to time in Naperville Community Unit School District 203. As a member of the American Speech-Language-Hearing Association, Ms. Ward was presented with the Award for Continuing Education in recognition of continued professional study.

    Aleisa Woodward (1st Grade, Oak) worked in Georgia's Whitfield County School System and then in Pleasantdale School District 107 in Burr Ridge, both for four years as a kindergarten teacher. Ms. Woodward most recently taught kindergarten and 2nd grade for one year each at The Lane. She has a B.S. in Early Childhood Education from the University of West Georgia.

    Polly Yukevich (Orchestra, District-wide) can command her novel District 181 students about an exciting project she completed with a previous district, in which she implemented a $7,000 ukulele grant and worked with world-renowned ukulele player Jake Shimabukuro. Ms. Yukevich besides led her students in a performance at the 2012 Illinois Music Educators Conference. Her previous districts involve Glenview Public School District 34 and Community Unit School District 300. Ms. Yukevich holds a B.M.Ed. from the VanderCook College of Music and an M.M.Ed. from the University of Illinois at Urbana-Champaign.

    Previously Employed (Moving to Full-Time OR novel Positions)

    The following individuals were previously employed in District 181 and own moved positions for the 2012-2013 school year and/or moved from part-time to full-time: Doug Eccarius, Jamie Guerin, Ehren Hill, Meghan Kappmeyer, Justine Legner, Eileen Logan, Joan Rickert, and Kevin Russell.

    Get the Hinsdale-Clarendon Hills newsletterSubscribe

    Thanks for your feedback.



    Direct Download of over 5500 Certification Exams

    3COM [8 Certification Exam(s) ]
    AccessData [1 Certification Exam(s) ]
    ACFE [1 Certification Exam(s) ]
    ACI [3 Certification Exam(s) ]
    Acme-Packet [1 Certification Exam(s) ]
    ACSM [4 Certification Exam(s) ]
    ACT [1 Certification Exam(s) ]
    Admission-Tests [13 Certification Exam(s) ]
    ADOBE [93 Certification Exam(s) ]
    AFP [1 Certification Exam(s) ]
    AICPA [2 Certification Exam(s) ]
    AIIM [1 Certification Exam(s) ]
    Alcatel-Lucent [13 Certification Exam(s) ]
    Alfresco [1 Certification Exam(s) ]
    Altiris [3 Certification Exam(s) ]
    Amazon [2 Certification Exam(s) ]
    American-College [2 Certification Exam(s) ]
    Android [4 Certification Exam(s) ]
    APA [1 Certification Exam(s) ]
    APC [2 Certification Exam(s) ]
    APICS [2 Certification Exam(s) ]
    Apple [69 Certification Exam(s) ]
    AppSense [1 Certification Exam(s) ]
    APTUSC [1 Certification Exam(s) ]
    Arizona-Education [1 Certification Exam(s) ]
    ARM [1 Certification Exam(s) ]
    Aruba [6 Certification Exam(s) ]
    ASIS [2 Certification Exam(s) ]
    ASQ [3 Certification Exam(s) ]
    ASTQB [8 Certification Exam(s) ]
    Autodesk [2 Certification Exam(s) ]
    Avaya [96 Certification Exam(s) ]
    AXELOS [1 Certification Exam(s) ]
    Axis [1 Certification Exam(s) ]
    Banking [1 Certification Exam(s) ]
    BEA [5 Certification Exam(s) ]
    BICSI [2 Certification Exam(s) ]
    BlackBerry [17 Certification Exam(s) ]
    BlueCoat [2 Certification Exam(s) ]
    Brocade [4 Certification Exam(s) ]
    Business-Objects [11 Certification Exam(s) ]
    Business-Tests [4 Certification Exam(s) ]
    CA-Technologies [21 Certification Exam(s) ]
    Certification-Board [10 Certification Exam(s) ]
    Certiport [3 Certification Exam(s) ]
    CheckPoint [41 Certification Exam(s) ]
    CIDQ [1 Certification Exam(s) ]
    CIPS [4 Certification Exam(s) ]
    Cisco [318 Certification Exam(s) ]
    Citrix [47 Certification Exam(s) ]
    CIW [18 Certification Exam(s) ]
    Cloudera [10 Certification Exam(s) ]
    Cognos [19 Certification Exam(s) ]
    College-Board [2 Certification Exam(s) ]
    CompTIA [76 Certification Exam(s) ]
    ComputerAssociates [6 Certification Exam(s) ]
    Consultant [2 Certification Exam(s) ]
    Counselor [4 Certification Exam(s) ]
    CPP-Institue [2 Certification Exam(s) ]
    CPP-Institute [1 Certification Exam(s) ]
    CSP [1 Certification Exam(s) ]
    CWNA [1 Certification Exam(s) ]
    CWNP [13 Certification Exam(s) ]
    Dassault [2 Certification Exam(s) ]
    DELL [9 Certification Exam(s) ]
    DMI [1 Certification Exam(s) ]
    DRI [1 Certification Exam(s) ]
    ECCouncil [21 Certification Exam(s) ]
    ECDL [1 Certification Exam(s) ]
    EMC [129 Certification Exam(s) ]
    Enterasys [13 Certification Exam(s) ]
    Ericsson [5 Certification Exam(s) ]
    ESPA [1 Certification Exam(s) ]
    Esri [2 Certification Exam(s) ]
    ExamExpress [15 Certification Exam(s) ]
    Exin [40 Certification Exam(s) ]
    ExtremeNetworks [3 Certification Exam(s) ]
    F5-Networks [20 Certification Exam(s) ]
    FCTC [2 Certification Exam(s) ]
    Filemaker [9 Certification Exam(s) ]
    Financial [36 Certification Exam(s) ]
    Food [4 Certification Exam(s) ]
    Fortinet [12 Certification Exam(s) ]
    Foundry [6 Certification Exam(s) ]
    FSMTB [1 Certification Exam(s) ]
    Fujitsu [2 Certification Exam(s) ]
    GAQM [9 Certification Exam(s) ]
    Genesys [4 Certification Exam(s) ]
    GIAC [15 Certification Exam(s) ]
    Google [4 Certification Exam(s) ]
    GuidanceSoftware [2 Certification Exam(s) ]
    H3C [1 Certification Exam(s) ]
    HDI [9 Certification Exam(s) ]
    Healthcare [3 Certification Exam(s) ]
    HIPAA [2 Certification Exam(s) ]
    Hitachi [30 Certification Exam(s) ]
    Hortonworks [4 Certification Exam(s) ]
    Hospitality [2 Certification Exam(s) ]
    HP [746 Certification Exam(s) ]
    HR [4 Certification Exam(s) ]
    HRCI [1 Certification Exam(s) ]
    Huawei [21 Certification Exam(s) ]
    Hyperion [10 Certification Exam(s) ]
    IAAP [1 Certification Exam(s) ]
    IAHCSMM [1 Certification Exam(s) ]
    IBM [1530 Certification Exam(s) ]
    IBQH [1 Certification Exam(s) ]
    ICAI [1 Certification Exam(s) ]
    ICDL [6 Certification Exam(s) ]
    IEEE [1 Certification Exam(s) ]
    IELTS [1 Certification Exam(s) ]
    IFPUG [1 Certification Exam(s) ]
    IIA [3 Certification Exam(s) ]
    IIBA [2 Certification Exam(s) ]
    IISFA [1 Certification Exam(s) ]
    Intel [2 Certification Exam(s) ]
    IQN [1 Certification Exam(s) ]
    IRS [1 Certification Exam(s) ]
    ISA [1 Certification Exam(s) ]
    ISACA [4 Certification Exam(s) ]
    ISC2 [6 Certification Exam(s) ]
    ISEB [24 Certification Exam(s) ]
    Isilon [4 Certification Exam(s) ]
    ISM [6 Certification Exam(s) ]
    iSQI [7 Certification Exam(s) ]
    ITEC [1 Certification Exam(s) ]
    Juniper [63 Certification Exam(s) ]
    LEED [1 Certification Exam(s) ]
    Legato [5 Certification Exam(s) ]
    Liferay [1 Certification Exam(s) ]
    Logical-Operations [1 Certification Exam(s) ]
    Lotus [66 Certification Exam(s) ]
    LPI [24 Certification Exam(s) ]
    LSI [3 Certification Exam(s) ]
    Magento [3 Certification Exam(s) ]
    Maintenance [2 Certification Exam(s) ]
    McAfee [8 Certification Exam(s) ]
    McData [3 Certification Exam(s) ]
    Medical [69 Certification Exam(s) ]
    Microsoft [368 Certification Exam(s) ]
    Mile2 [2 Certification Exam(s) ]
    Military [1 Certification Exam(s) ]
    Misc [1 Certification Exam(s) ]
    Motorola [7 Certification Exam(s) ]
    mySQL [4 Certification Exam(s) ]
    NBSTSA [1 Certification Exam(s) ]
    NCEES [2 Certification Exam(s) ]
    NCIDQ [1 Certification Exam(s) ]
    NCLEX [2 Certification Exam(s) ]
    Network-General [12 Certification Exam(s) ]
    NetworkAppliance [36 Certification Exam(s) ]
    NI [1 Certification Exam(s) ]
    NIELIT [1 Certification Exam(s) ]
    Nokia [6 Certification Exam(s) ]
    Nortel [130 Certification Exam(s) ]
    Novell [37 Certification Exam(s) ]
    OMG [10 Certification Exam(s) ]
    Oracle [269 Certification Exam(s) ]
    P&C [2 Certification Exam(s) ]
    Palo-Alto [4 Certification Exam(s) ]
    PARCC [1 Certification Exam(s) ]
    PayPal [1 Certification Exam(s) ]
    Pegasystems [11 Certification Exam(s) ]
    PEOPLECERT [4 Certification Exam(s) ]
    PMI [15 Certification Exam(s) ]
    Polycom [2 Certification Exam(s) ]
    PostgreSQL-CE [1 Certification Exam(s) ]
    Prince2 [6 Certification Exam(s) ]
    PRMIA [1 Certification Exam(s) ]
    PsychCorp [1 Certification Exam(s) ]
    PTCB [2 Certification Exam(s) ]
    QAI [1 Certification Exam(s) ]
    QlikView [1 Certification Exam(s) ]
    Quality-Assurance [7 Certification Exam(s) ]
    RACC [1 Certification Exam(s) ]
    Real-Estate [1 Certification Exam(s) ]
    RedHat [8 Certification Exam(s) ]
    RES [5 Certification Exam(s) ]
    Riverbed [8 Certification Exam(s) ]
    RSA [15 Certification Exam(s) ]
    Sair [8 Certification Exam(s) ]
    Salesforce [5 Certification Exam(s) ]
    SANS [1 Certification Exam(s) ]
    SAP [98 Certification Exam(s) ]
    SASInstitute [15 Certification Exam(s) ]
    SAT [1 Certification Exam(s) ]
    SCO [10 Certification Exam(s) ]
    SCP [6 Certification Exam(s) ]
    SDI [3 Certification Exam(s) ]
    See-Beyond [1 Certification Exam(s) ]
    Siemens [1 Certification Exam(s) ]
    Snia [7 Certification Exam(s) ]
    SOA [15 Certification Exam(s) ]
    Social-Work-Board [4 Certification Exam(s) ]
    SpringSource [1 Certification Exam(s) ]
    SUN [63 Certification Exam(s) ]
    SUSE [1 Certification Exam(s) ]
    Sybase [17 Certification Exam(s) ]
    Symantec [134 Certification Exam(s) ]
    Teacher-Certification [4 Certification Exam(s) ]
    The-Open-Group [8 Certification Exam(s) ]
    TIA [3 Certification Exam(s) ]
    Tibco [18 Certification Exam(s) ]
    Trainers [3 Certification Exam(s) ]
    Trend [1 Certification Exam(s) ]
    TruSecure [1 Certification Exam(s) ]
    USMLE [1 Certification Exam(s) ]
    VCE [6 Certification Exam(s) ]
    Veeam [2 Certification Exam(s) ]
    Veritas [33 Certification Exam(s) ]
    Vmware [58 Certification Exam(s) ]
    Wonderlic [2 Certification Exam(s) ]
    Worldatwork [2 Certification Exam(s) ]
    XML-Master [3 Certification Exam(s) ]
    Zend [6 Certification Exam(s) ]





    References :


    Dropmark : http://killexams.dropmark.com/367904/11958654
    Dropmark-Text : http://killexams.dropmark.com/367904/12904135
    Blogspot : http://killexamsbraindump.blogspot.com/2017/12/get-high-marks-in-bcba-exam-with-these.html
    RSS Feed : http://feeds.feedburner.com/FreePass4sureBcbaQuestionBank
    Wordpress : https://wp.me/p7SJ6L-2ku
    Box.net : https://app.box.com/s/r3o1e2uy1gpnl7p20rgf3ljfdonce02r






    Back to Main Page





    Killexams exams | Killexams certification | Pass4Sure questions and answers | Pass4sure | pass-guaratee | best test preparation | best training guides | examcollection | killexams | killexams review | killexams legit | kill example | kill example journalism | kill exams reviews | kill exam ripoff report | review | review quizlet | review login | review archives | review sheet | legitimate | legit | legitimacy | legitimation | legit check | legitimate program | legitimize | legitimate business | legitimate definition | legit site | legit online banking | legit website | legitimacy definition | pass 4 sure | pass for sure | p4s | pass4sure certification | pass4sure exam | IT certification | IT Exam | certification material provider | pass4sure login | pass4sure exams | pass4sure reviews | pass4sure aws | pass4sure security | pass4sure cisco | pass4sure coupon | pass4sure dumps | pass4sure cissp | pass4sure braindumps | pass4sure test | pass4sure torrent | pass4sure download | pass4surekey | pass4sure cap | pass4sure free | examsoft | examsoft login | exams | exams free | examsolutions | exams4pilots | examsoft download | exams questions | examslocal | exams practice |

    www.pass4surez.com | www.killcerts.com | www.search4exams.com | http://www.radionaves.com/